Medical

A public/private partnership in Louisville, Kentucky called AIR Louisville will distribute 2,000 Propeller Health inhaler sensors to asthma patients across the city as part of a 2-year data collection program, according to Propeller. The FDA approved an updated version of the asthma tracking system, which includes sensors that snap onto standard MDIs, in April 2014. … [Read more...] about Louiville, KY launches citywide inhaler sensor distribution program

AstraZeneca has announced that data from two Phase 3 studies of its PT003 glycopyrronium/formoterol MDI for the treatment of COPD showed statistically significant improvements in lung function for patients using PT003 compared to each of its components and to placebo. In 2013, Pearl Therapeutics announced the initiation of the Phase 3 program less than a month before … [Read more...] about Positive Phase 3 results for PT003 glycopyrronium/formoterol MDI

Data to be presented at the upcoming annual meeting of The Endocrine Society show that healthy men treated with intranasal oxytocin consumed fewer calories and had reduced insulin sensitivity after use of the nasal spray. The randomized, placebo-controlled study, conducted by researchers from Harvard Medical School, involved 25 men, half of whom were normal weight and … [Read more...] about Study shows oxytocin nasal spray lowers calorie intake in men

Adamis Pharmaceuticals has announced that data from a Phase 1 PK study its APC-5000 fluticasone/salmeterol DPI, a generic carrier-free version of Advair Diskus, show less systemic exposure to both components compared to Advair. The open-label study compared 3 inhalations of APC-5000 to 3 inhalations of Advair Diskus in 16 healthy subjects over 4 treatment … [Read more...] about Adamis announces positive Phase 1 results for its fluticasone/salmeterol DPI

A Phase 3 trial program of Sunovion Pharmaceutical's SUN-101 glycopyrrolate inhalation solution for the treatment of moderate-to-very severe COPD has begun enrolling patients, the company announced. The program includes three studies expected to enroll about 2,340 COPD patients. SUN-101 is delivered using PARI's eFlow nebulizer system and, if approved, would be the … [Read more...] about Sunovion initiates Phase 3 program for glycopyrrolate inhalation solution

Boehringer Ingelheim has presented data from five Phase 3 trials of tiotropium Respimat for the treatment of asthma at the 2015 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting. The data come from two PrimoTinA-asthma trials (severe asthma), two MezzoTinA-asthma trials (moderate asthma), and a single GraziaTinA-asthma trial (mild asthma). … [Read more...] about Boehringer Ingelheim presents data from Phase 3 trials of tiotropium Respimat

Savara Pharmaceuticals has announced positive results from a Phase 2 trial of its AeroVanc vancomycin DPI for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) lung infections in cystic fibrosis patients. In the 28-day trial, patients treated with AeroVanc had a statistically significant reduction in MRSA density in sputum compared to patients … [Read more...] about Positive Phase 2 results for Savara’s AeroVanc

GlaxoSmithKline and Theravance have announced the beginning of the FULFIL (Lung FUnction and quality of LiFe assessment in COPD with closed trIpLe therapy) Phase 3 study of a fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) DPI in patients with COPD. The randomized double-blind study is expected to enroll approximately 1,800 patients. An earlier Phase 3 study … [Read more...] about GSK and Theravance initiate Phase 3 study of triple combination inhaler